AI-driven electronic olfaction (smelltech) and point-of-care diagnostics
Strategic Profile
The company provides its platforms for semiconductor manufacturing, robotics, and smart manufacturing industries, as well as senior care and women's health sectors. Ainos operates as a micro-cap public company with emerging technology in artificial olfaction and biotech therapeutics, though it remains pre-profitability with significant execution risk.
Cyborg Score Rationale
Ainos operates in cutting-edge smelltech and immune therapeutics with novel technology platforms and demonstrated revenue growth (499% YoY in fiscal year 2026), but faces significant challenges including micro-cap valuation (~$14-16M), unprofitability, minimal employee base (41 staff), and early-stage clinical development. The company's dual-platform diversification presents both strategic opportunity and execution risk.
Top Insights
Ainos released its 2026 mid-year shareholder letter reporting 499% year-over-year revenue growth during fiscal year 2026
Ainos, Inc. is a subsidiary of Taiwan Carbon Nano Technology Corporation, providing strategic backing and Asian market access
The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021; it was incorporated in 1984 and is based in Houston, Texas
Micro-cap trading dynamics with high volatility (52-week range $1.26-$4.50 as of mid-July 2026) reflect speculative positioning typical of early-stage biotech and emerging AI platforms
Named Competitors
Interferon therapeutics — Alternative interferon-based therapeutics for immunomodulation
Aryballe — AI-driven digital olfaction platform using silicon photonics and biosensors for scent detection and analysis
Aromajoin — Scent controllable technology and digital olfaction platform for fragmentrance digitalization
Osmo — Digital olfaction startup providing scent sensing and analysis technology
Recent Developments
(June 2026) National Taiwan University research program announced to study AI Nose applications
(Q2 2026) VASRO GmbH published research report discussing Ainos' AI Nose expansion
(H1 2026) Announced strategic partnership expansion with ASE Technology Holding to deploy up to 15,000 AI Nose units across key sites
Open the full interactive Ainos, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.